418759-83-8

Upstream product

• 418760-03-9 (2R,3S)-5-Azido-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-ol 
• 367518-84-1 3,5-di-O-acetyl-2-deoxy-D-ribofuranosyl azide 
• 418760-15-3 2-deoxy-α,β-D-erythropentofuranosyl azide 
• 4594-52-9 1,3,5-tri-O-acetyl-2-deoxyribose 
• 833480-25-4 {(2R,3S)-5-Azido-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-yloxy}-tert-butyl-dimethyl-silane 

Downstream Products

• 833480-26-5 2-amino-6-[5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-ylamino]-5-nitro-3H-pyrimidin-4-one 
• 833480-39-0 C₆₀H₇₅N₈O₁₆PSi 
• 833480-38-9 C₅₉H₇₃N₈O₁₇PSi 
• 833480-33-4 C₅₉H₇₄N₇O₁₆PSi 
• 833480-32-3 C₅₉H₇₄N₇O₁₆PSi 
• 833480-31-2 C₅₈H₇₂N₇O₁₇PSi 
• 833480-30-1 C₅₈H₇₂N₇O₁₇PSi 
• 833480-40-3 C₅₄H₆₁N₈O₁₆P 
• 833480-34-5 C₅₃H₆₀N₇O₁₆P 
• 833480-27-6 N-{4-[5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-ylamino]-5-nitro-6-oxo-1,6-dihydro-pyrimidin-2-yl}-2-(4-isopropyl-phenoxy)-acetamide 
• 1053709-88-8 N-{4-[4-(tert-butyl-dimethyl-silanyloxy)-5-hydroxymethyl-tetrahydro-furan-2-ylamino]-5-nitro-6-oxo-1,6-dihydro-pyrimidin-2-yl}-2-(4-isopropyl-phenoxy)-acetamide 
• 1053264-62-2 N-{4-[4-(tert-butyl-dimethyl-silanyloxy)-5-hydroxymethyl-tetrahydro-furan-2-ylamino]-5-nitro-6-oxo-1,6-dihydro-pyrimidin-2-yl}-2-(4-isopropyl-phenoxy)-acetamide 

Relevant academic research and scientific papers

Synthesis of oligonucleotides containing Fapy·dG (N 6-(2-deoxy-α,β-D-erythropentofuranosyl)-2, 6-diamino-4-hydroxy-5-formamidopyrimidine) using a 5′-dimethoxytrityl dinucleotide phosphoramidite

(Chemical Equation Presented). Fapy·dG (N6-(2-deoxy- α,β-D-erythropentofuranosyl)-2,6-diamino-4-hydroxy-5- formamidopyrimidine) is a modified purine lesion produced by a variety of DNA-damaging agents, which shows interesting biochemical proper

Synthesis and characterization of oligodeoxynucleotides containing formamidopyrimidine lesions and nonhydrolyzable analogues

Oligodeoxynucleotides containing formamidopyrimidine lesions and C-nucleoside analogues at defined sites were prepared by solid-phase synthesis and in some cases enzymatic ligation. Formamidopyrimidine lesions were introduced as dinucleotides to prevent r